Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jan 18;82(2):452–458. doi: 10.1054/bjoc.1999.0942

Novel therapeutic approach: organic arsenical (melarsoprol) alone or with all-trans -retinoic acid markedly inhibit growth of human breast and prostate cancer cells in vitro and in vivo

K Koshiuka 1, E Elstner 1, E Williamson 1, J W Said 2, Y Tada 1, H P Koeffler 1
PMCID: PMC2363281  PMID: 10646904

Abstract

The organic arsenical known as melarsoprol (Mel-B) is used to treat African trypanosomiasis. Recently, another arsenical, As2O3was shown to be effective in treatment of acute promyelocytic leukaemia. We have investigated the anti-tumour activities of Mel-B either with or without all-trans -retinoic acid (ATRA) using the MCF-7 human breast cancer cells, as well as the PC-3 and DU 145 human prostate cancer cells both in vitro and in vivo. The antiproliferative effects of Mel-B and/or ATRA against breast and prostate cancer were tested in vitro using clonogenic assays and in vivo in triple immunodeficient mice. Furthermore, the mechanism of action of these compounds was studied by examining the cell cycle, levels of bcl-2, apoptosis and antiproliferative potency using a pulse-exposure assay. Clonogenic assays showed that the cancer cell lines were sensitive to the inhibitory effect of Mel-B (effective dose that inhibited 50% clonal growth [ED50]: 7 × 10−9M for MCF-7, 2 × 10−7M for PC-3, 3 × 10−7M for DU145 cells. Remarkably, the combination of Mel-B and ATRA had an enhanced antiproliferative activity against all three cancer cell lines. Furthermore, the combination of Mel-B and ATRA induced a high level of apoptosis in all three cell lines. Treatment of PC-3 and MCF-7 tumours growing in triple immunodeficient mice with Mel-B and ATRA either alone or in combination markedly retarded tumour size and weight of the tumours without major side-effects. In conclusion, our results suggest that either Mel-B alone or with ATRA may be a useful, novel therapy for breast and prostate cancers. © 2000 Cancer Research Campaign

Keywords: melarsoprol, retinoid, breast cancer, prostate cancer, apoptosis

Full Text

The Full Text of this article is available as a PDF (256.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bollag W., Holdener E. E. Retinoids in cancer prevention and therapy. Ann Oncol. 1992 Jul;3(7):513–526. doi: 10.1093/oxfordjournals.annonc.a058252. [DOI] [PubMed] [Google Scholar]
  2. Borsellino N., Belldegrun A., Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 1995 Oct 15;55(20):4633–4639. [PubMed] [Google Scholar]
  3. Campbell M. J., Dawson M., Koeffler H. P. Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl)all-trans retinamide. Br J Cancer. 1998 Mar;77(5):739–744. doi: 10.1038/bjc.1998.121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Campbell M. J., Park S., Uskokovic M. R., Dawson M. I., Koeffler H. P. Expression of retinoic acid receptor-beta sensitizes prostate cancer cells to growth inhibition mediated by combinations of retinoids and a 19-nor hexafluoride vitamin D3 analog. Endocrinology. 1998 Apr;139(4):1972–1980. doi: 10.1210/endo.139.4.5943. [DOI] [PubMed] [Google Scholar]
  5. Cavigelli M., Li W. W., Lin A., Su B., Yoshioka K., Karin M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J. 1996 Nov 15;15(22):6269–6279. [PMC free article] [PubMed] [Google Scholar]
  6. Chen G. Q., Shi X. G., Tang W., Xiong S. M., Zhu J., Cai X., Han Z. G., Ni J. H., Shi G. Y., Jia P. M. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997 May 1;89(9):3345–3353. [PubMed] [Google Scholar]
  7. Chen G. Q., Zhu J., Shi X. G., Ni J. H., Zhong H. J., Si G. Y., Jin X. L., Tang W., Li X. S., Xong S. M. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996 Aug 1;88(3):1052–1061. [PubMed] [Google Scholar]
  8. Chen W., Martindale J. L., Holbrook N. J., Liu Y. Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Shc. Mol Cell Biol. 1998 Sep;18(9):5178–5188. doi: 10.1128/mcb.18.9.5178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dong J. T., Luo X. M. Effects of arsenic on DNA damage and repair in human fetal lung fibroblasts. Mutat Res. 1994 Jul;315(1):11–15. doi: 10.1016/0921-8777(94)90022-1. [DOI] [PubMed] [Google Scholar]
  10. Douer D., Koeffler H. P. Retinoic acid. Inhibition of the clonal growth of human myeloid leukemia cells. J Clin Invest. 1982 Feb;69(2):277–283. doi: 10.1172/JCI110450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Elstner E., Linker-Israeli M., Le J., Umiel T., Michl P., Said J. W., Binderup L., Reed J. C., Koeffler H. P. Synergistic decrease of clonal proliferation, induction of differentiation, and apoptosis of acute promyelocytic leukemia cells after combined treatment with novel 20-epi vitamin D3 analogs and 9-cis retinoic acid. J Clin Invest. 1997 Jan 15;99(2):349–360. doi: 10.1172/JCI119164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Evans R. M. The steroid and thyroid hormone receptor superfamily. Science. 1988 May 13;240(4854):889–895. doi: 10.1126/science.3283939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Fisher D. E. Apoptosis in cancer therapy: crossing the threshold. Cell. 1994 Aug 26;78(4):539–542. doi: 10.1016/0092-8674(94)90518-5. [DOI] [PubMed] [Google Scholar]
  14. Giannì M., Koken M. H., Chelbi-Alix M. K., Benoit G., Lanotte M., Chen Z., de Thé H. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood. 1998 Jun 1;91(11):4300–4310. [PubMed] [Google Scholar]
  15. Gudas L. J. Retinoids, retinoid-responsive genes, cell differentiation, and cancer. Cell Growth Differ. 1992 Sep;3(9):655–662. [PubMed] [Google Scholar]
  16. Huang M. E., Ye Y. C., Chen S. R., Chai J. R., Lu J. X., Zhoa L., Gu L. J., Wang Z. Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988 Aug;72(2):567–572. [PubMed] [Google Scholar]
  17. Israel K., Sanders B. G., Kline K. RRR-alpha-tocopheryl succinate inhibits the proliferation of human prostatic tumor cells with defective cell cycle/differentiation pathways. Nutr Cancer. 1995;24(2):161–169. doi: 10.1080/01635589509514404. [DOI] [PubMed] [Google Scholar]
  18. Jaafar R., Omar I., Jidon A. J., Wan-Khamizar B. W., Siti-Aishah B. M., Sharifah-Noor-Akmal S. H. Skin cancer caused by chronic arsenical poisoning--a report of three cases. Med J Malaysia. 1993 Mar;48(1):86–92. [PubMed] [Google Scholar]
  19. König A., Wrazel L., Warrell R. P., Jr, Rivi R., Pandolfi P. P., Jakubowski A., Gabrilove J. L. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood. 1997 Jul 15;90(2):562–570. [PubMed] [Google Scholar]
  20. Li X., Darzynkiewicz Z. Labelling DNA strand breaks with BrdUTP. Detection of apoptosis and cell proliferation. Cell Prolif. 1995 Nov;28(11):571–579. doi: 10.1111/j.1365-2184.1995.tb00045.x. [DOI] [PubMed] [Google Scholar]
  21. Mervis J. Ancient remedy performs new tricks. Science. 1996 Aug 2;273(5275):578–578. doi: 10.1126/science.273.5275.578. [DOI] [PubMed] [Google Scholar]
  22. Milord F., Pépin J., Loko L., Ethier L., Mpia B. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet. 1992 Sep 12;340(8820):652–655. doi: 10.1016/0140-6736(92)92180-n. [DOI] [PubMed] [Google Scholar]
  23. Miyashita T., Reed J. C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 1993 Jan 1;81(1):151–157. [PubMed] [Google Scholar]
  24. Munker R., Norman A., Koeffler H. P. Vitamin D compounds. Effect on clonal proliferation and differentiation of human myeloid cells. J Clin Invest. 1986 Aug;78(2):424–430. doi: 10.1172/JCI112593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Petkovich M. Regulation of gene expression by vitamin A: the role of nuclear retinoic acid receptors. Annu Rev Nutr. 1992;12:443–471. doi: 10.1146/annurev.nu.12.070192.002303. [DOI] [PubMed] [Google Scholar]
  26. Pienta K. J., Nguyen N. M., Lehr J. E. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res. 1993 Jan 15;53(2):224–226. [PubMed] [Google Scholar]
  27. Shi Y., Glynn J. M., Guilbert L. J., Cotter T. G., Bissonnette R. P., Green D. R. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science. 1992 Jul 10;257(5067):212–214. doi: 10.1126/science.1378649. [DOI] [PubMed] [Google Scholar]
  28. Snow E. T. Metal carcinogenesis: mechanistic implications. Pharmacol Ther. 1992;53(1):31–65. doi: 10.1016/0163-7258(92)90043-y. [DOI] [PubMed] [Google Scholar]
  29. Soignet S. L., Maslak P., Wang Z. G., Jhanwar S., Calleja E., Dardashti L. J., Corso D., DeBlasio A., Gabrilove J., Scheinberg D. A. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998 Nov 5;339(19):1341–1348. doi: 10.1056/NEJM199811053391901. [DOI] [PubMed] [Google Scholar]
  30. Symonds H., Krall L., Remington L., Saenz-Robles M., Lowe S., Jacks T., Van Dyke T. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 1994 Aug 26;78(4):703–711. doi: 10.1016/0092-8674(94)90534-7. [DOI] [PubMed] [Google Scholar]
  31. Teelmann K., Tsukaguchi T., Klaus M., Eliason J. F. Comparison of the therapeutic effects of a new arotinoid, Ro 40-8757, and all-trans- and 13-cis-retinoic acids on rat breast cancer. Cancer Res. 1993 May 15;53(10 Suppl):2319–2325. [PubMed] [Google Scholar]
  32. Thompson C. B. Apoptosis in the pathogenesis and treatment of disease. Science. 1995 Mar 10;267(5203):1456–1462. doi: 10.1126/science.7878464. [DOI] [PubMed] [Google Scholar]
  33. Van Nieuwenhove S. Advances in sleeping sickness therapy. Ann Soc Belg Med Trop. 1992;72 (Suppl 1):39–51. [PubMed] [Google Scholar]
  34. Warrell R. P., Jr, de Thé H., Wang Z. Y., Degos L. Acute promyelocytic leukemia. N Engl J Med. 1993 Jul 15;329(3):177–189. doi: 10.1056/NEJM199307153290307. [DOI] [PubMed] [Google Scholar]
  35. Yonish-Rouach E., Resnitzky D., Lotem J., Sachs L., Kimchi A., Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 1991 Jul 25;352(6333):345–347. doi: 10.1038/352345a0. [DOI] [PubMed] [Google Scholar]
  36. Yunmbam M. K., Roberts J. F. In vivo evaluation of reuterin and its combinations with suramin, melarsoprol, DL-alpha-difluoromethylornithine and bleomycin in mice infected with Trypanosoma brucei brucei. Comp Biochem Physiol C. 1993 Jul;105(3):521–524. doi: 10.1016/0742-8413(93)90095-3. [DOI] [PubMed] [Google Scholar]
  37. de Vos S., Dawson M. I., Holden S., Le T., Wang A., Cho S. K., Chen D. L., Koeffler H. P. Effects of retinoid X receptor-selective ligands on proliferation of prostate cancer cells. Prostate. 1997 Jul 1;32(2):115–121. doi: 10.1002/(sici)1097-0045(19970701)32:2<115::aid-pros6>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES